Aptus Pharma Limited Hits Upper Circuit on BSE, 28 September 2026

On 28 September 2026, Aptus Pharma Limited (APPL) hit the upper circuit on BSE at Rs 353.9, a 1.99% positive move from the previous close of Rs 347. The company’s market cap stood at Rs 595.11 crore. The upper circuit price for the session was Rs 353.9.

The move was driven by buying interest against the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Key Takeaways

• Aptus Pharma Limited (APPL) hit the upper circuit on BSE at Rs 353.9 on 28 September 2026.
• The session move was +1.99% against a previous close of Rs 347.
• Market capitalisation stood at Rs 595.11 crore with a PE ratio of 128.81.
• No official company announcement or verified catalyst was confirmed at the time of writing.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

All figures above are as of 28 September 2026, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Aptus Pharma Limited opened at Rs 348.7 on BSE, compared with a previous close of Rs 347. During the session, the stock traded between Rs 348.7 and Rs 353.9 before touching the upper circuit price of Rs 353.9.

The absolute day change was Rs 6.9, while the percentage move was 1.99%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 353.9, which is the level the price reached.

Why Aptus Pharma Limited Hit Upper Circuit

Aptus Pharma Limited hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 353.9.

What the Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Aptus Pharma Limited, the captured upper circuit price was Rs 353.9 on 28 September 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Aptus Pharma Limited Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Aptus Pharma Limited, PE ratio was 128.81, PB ratio was 17.69, book value was Rs 19.61, EPS was 2.69, ROE was 30.48%, ROCE was 30.01%, dividend yield was 0% and debt-to-assets ratio was 0.31, on a market cap of Rs 595.11 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

At the reported PB ratio of 17.69, the market valued Aptus Pharma Limited above its reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Aptus Pharma Limited belongs to the Trading industry. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Several of these peers are far larger by market capitalisation than Aptus Pharma Limited. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Aptus Pharma Limited’s PE ratio was 128.81, compared with an available peer PE average of 81.32, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical Snapshot

The technical snapshot adds context: RSI was 69.29, the 50-day moving average was 329.29 and the 200-day moving average was 222.88.

What Readers Should Know

The main confirmed fact is that Aptus Pharma Limited hit the upper circuit on BSE at Rs 353.9 on 28 September 2026, with a 1.99% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Aptus Pharma Limited hit upper circuit on 28 September 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was APPL share price on 28 September 2026?

The last traded price used in this article was Rs 353.9 on BSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for APPL?

The upper circuit price was Rs 353.9. The stated exchange upper circuit limit was Rs 353.9. The event numbers in this article are aligned to BSE.

What is Aptus Pharma Limited’s market cap and PE ratio?

Aptus Pharma Limited’s market cap was Rs 595.11 crore. PE ratio was 128.81.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 28 September 2026.

Does hitting an upper circuit mean Aptus Pharma Limited is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Aptus Pharma Limited shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Aptus Pharma Limited the stated limit was Rs 353.9. For this session, Aptus Pharma Limited moved 1.99%.

Footer Disclosure